Q-omics provides the consensus-scored IL6 profile across patient tissues and cancer cell-line models. IL6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL6 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, IL6 RNA expression shows 15,540 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where IL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL6 survival associations across molecular data types. IL6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL6 RNA expression–survival associations across cancer types. High IL6 expression shows unfavorable associations in KIRP, UVM, KIRC, LGG, LUSC and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL6 RNA expression.
This table summarizes IL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL6 shows lower tumor expression in KICH, BLCA, LUAD, BRCA and LUSC and higher tumor expression in COAD. The KICH box plot shows higher IL6 RNA expression in normal versus tumor tissue (log2 FC = −4.302, t-test p < 0.001).
This table shows molecular features associated with IL6 in patient tissues and cancer cell lines. In patient samples, IL6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and KIDNEY.
